MorphoSys Finds Right Time To Focus On Pipeline With AbD Serotec Sale To Bio-Rad Labs
This article was originally published in The Pink Sheet Daily
MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.
You may also be interested in...
Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.
Morphosys and Celgene have agreed to jointly develop MOR202 for multiple myeloma, and to co-promote it in Europe. The deal allows Morphosys for the first time to participate in the commercialization of one of its products and decisively validates commercial interest in one of the industry’s hot oncology targets
The British pharma is expanding its portfolio in rheumatoid arthritis through a mid-stage tie-up with German biotech MorphoSys. GSK will take over all development of the antibody and could pay milestones up to €425 million.